S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Mesoblast Stock Forecast, Price & News

-0.26 (-4.75%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
192,094 shs
Average Volume
164,396 shs
Market Capitalization
$675.95 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Mesoblast logo

About Mesoblast

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.


Mesoblast (NASDAQ:MESO) Sets New 1-Year Low at $5.38
December 2, 2021 |  americanbankingnews.com
Mesoblast (NASDAQ:MESO) Trading Up 9.9%
November 23, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$7.46 million
Book Value
$4.31 per share


Net Income
$-98.81 million
Net Margins
Pretax Margin




Free Float
Market Cap
$675.95 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.93 out of 5 stars

Medical Sector

709th out of 1,388 stocks

Biological Products, Except Diagnostic Industry

110th out of 202 stocks

Analyst Opinion: 3.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

Is Mesoblast a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Mesoblast stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View analyst ratings for Mesoblast
or view top-rated stocks.

How has Mesoblast's stock been impacted by COVID-19?

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MESO stock has decreased by 13.5% and is now trading at $5.21.
View which stocks have been most impacted by COVID-19

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Mesoblast

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) posted its quarterly earnings results on Sunday, August, 29th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.09. The business earned $2 million during the quarter, compared to analyst estimates of $8.23 million. Mesoblast had a negative net margin of 994.48% and a negative trailing twelve-month return on equity of 17.15%.
View Mesoblast's earnings history

What price target have analysts set for MESO?

5 brokers have issued 1-year target prices for Mesoblast's shares. Their forecasts range from $6.50 to $18.00. On average, they anticipate Mesoblast's share price to reach $13.50 in the next year. This suggests a possible upside of 159.1% from the stock's current price.
View analysts' price targets for Mesoblast
or view top-rated stocks among Wall Street analysts.

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Silviu Itescu, Chief Executive Officer, MD & Executive Director
  • Dagmar Rosa-Bjorkeson, Chief Operating Officer
  • Andrew Chaponnel, Chief Financial Officer & Head-Finance
  • Fred Grossman, Chief Medical Officer
  • Michael Schuster, Head-Pharma Partnering

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by many different institutional and retail investors. Top institutional investors include M&G Investment Management Ltd. (1.02%), BlackRock Inc. (0.62%), Hennion & Walsh Asset Management Inc. (0.30%), Penbrook Management LLC (0.19%), Morgan Stanley (0.16%) and Jacob Asset Management of New York LLC (0.13%).

Which institutional investors are selling Mesoblast stock?

MESO stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Morgan Stanley, Jacob Asset Management of New York LLC, Goldman Sachs Group Inc., LPL Financial LLC, and Penbrook Management LLC.

Which institutional investors are buying Mesoblast stock?

MESO stock was bought by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Hennion & Walsh Asset Management Inc., BlackRock Inc., Cetera Advisor Networks LLC, and Cambridge Investment Research Advisors Inc..

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $5.21.

How much money does Mesoblast make?

Mesoblast has a market capitalization of $675.95 million and generates $7.46 million in revenue each year. The company earns $-98.81 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Mesoblast have?

Mesoblast employs 102 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

Where are Mesoblast's headquarters?

Mesoblast is headquartered at LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at (139) 639-6036, via email at [email protected], or via fax at 61-3-9639-6030.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.